Bifidobacterium breve için Irritable Bowel Syndrome (IBS)

Q: Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?

Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).

Q: How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?

Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Bifidobacterium breve?

Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?

We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Limited data from small studies. Preliminary evidence for symptom improvement.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Sonuç

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review

Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: None

Other n=1098 8 weeks Open-label

A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …

Dose: None vs: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Etki: 73% pain, 81.9% bloating success at T1 <0.001

Popülasyon: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind

Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …

Dose: None vs: Placebo Outcome: IBS-SSS symptom severity score change Etki: None None

Popülasyon: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks

Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …

Dose: 2 g vs: Placebo Outcome: Constipation symptoms Etki: None P = 0.005

Popülasyon: IBS patients

Review

Postbiotics: A new member in the biotics family.

Dose: None vs: None Outcome: Clinical applications overview Etki: None None

Popülasyon: General population (review)

In Vitro

Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …

Dose: None vs: None Outcome: Colitis severity Etki: None None

Popülasyon: Crohn's disease patients

Key Statistics

Çalışmalar

150

Katılımcılar

↑

Positive

Derece

Referenced Papers

Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases. Review

Microbiome research reports 2025 16 atıf

A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. Other

Beneficial microbes 2025

Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results … Other

Frontiers in nutrition 2025

Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … Other

The Yale journal … 2024 5 atıf

Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Other

Journal of neurogastroenterology … 2024 4 atıf

Postbiotics: A new member in the biotics family. Other

Archivos argentinos de … 2024 3 atıf

Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis. Other

Cureus 2024 1 atıf

Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. Other

Journal of translational … 2023 30 atıf

Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice. Other

Nutrients 2023 19 atıf

Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … Other

Journal of neurogastroenterology … 2022 21 atıf

Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. Other

Journal of microbiology … 2022 15 atıf

Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. Other

Scientific reports 2022 14 atıf

Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. Systematic Review

Journal of clinical … 2018 34 atıf

Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … Other

Journal of clinical … 2015 62 atıf

Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Meta-Analysis

Revista espanola de … 2013 102 atıf

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … RCT

Journal of clinical … 2012 207 atıf

Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel … Other

PloS one 2012 31 atıf

BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? Other

Beneficial microbes 2011 89 atıf

The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Other

Neurogastroenterology and motility 2010 213 atıf

Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. RCT

BMC gastroenterology 2010 91 atıf

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. RCT

Alimentary pharmacology & … 2007 102 atıf

Clinical studies on alleviating the symptoms of irritable bowel syndrome. RCT

Asia Pacific journal … 2006

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. RCT

Alimentary pharmacology & … 2005 398 atıf

Probiotics in the treatment of irritable bowel syndrome. RCT

Journal of clinical … 2004 205 atıf

Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome … Other

Research in microbiology 2001 201 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:: 1-10 billion CFU/day
adultgisupport:: 5-10 billion CFU/day
neonatalsupport:: 1-5 billion CFU/day (as directed by pediatrician)

Üst sınır: Well-tolerated up to 10 billion CFU/day in clinical trials

Araştırmalarda İncelenen Dozajlar

Dozaj	Süre	Etki	N
None	--	Mixed	--
None	8 weeks	Positive	1098
None	8 weeks	Neutral	61
2 g	4 weeks	Mixed	--
None	--	Positive	--
None	--	Positive	--
Serum-derived bovine immunoglobulin (SBI)	--	Positive	--
None	--	Positive	--

En iyi alım zamanı: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Bildirilen Yan Etkiler

⚠ Mild gas during initial use
⚠ Occasional loose stools in infants (transient)
⚠ Rare abdominal discomfort
⚠ Very rare: bacteremia in immunocompromised individuals

Bilinen Etkileşimler

● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
● Immunosuppressants (use with caution in immunocompromised patients)

Tolere edilebilir üst alım: Well-tolerated up to 10 billion CFU/day in clinical trials

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?

Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).

How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?

Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Bifidobacterium breve?

Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?

We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Irritable Bowel Syndrome (IBS)

Peppermint Oil A Lactobacillus rhamnosus GG B Psyllium Husk B Lactobacillus plantarum B Partially Hydrolyzed Guar Gum (PHGG) B Bifidobacterium longum B

Hızlı Değerlendirme

Limited data from small studies. Preliminary evidence for symptom improvement.

Evidence Strength30%

Low confidence

Çalışma Dağılımı

RCT (6)Meta (1)Other (0)

Alternatifleri Karşılaştır

Bu durum için diğer bileşenlerin nasıl karşılaştırıldığını görün.Diğer içeriklerin bu sağlık durumu için nasıl karşılaştırıldığını görün.

Şu durum için tüm içerikleri görüntüle: Irritable Bowel Syndrome (IBS)

Daha Fazla Bilgi

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.